[
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) Comes Up With A Good Thing But No One Cares, Laments Jim Cramer",
    "summary": "We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently discussed. Pfizer Inc. (NYSE:PFE)’s shares jumped by 1.8% earlier this week after the firm announced that its bladder cancer drug Padcev helped improve bladder cancer survival rates when combined with Merck’s […]",
    "url": "https://finnhub.io/api/news?id=e648541a1fdef3b7c8f532dcc7dabef45ee06cc247753bd47fc43993154e930d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755282660,
      "headline": "Pfizer Inc. (PFE) Comes Up With A Good Thing But No One Cares, Laments Jim Cramer",
      "id": 136376321,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently discussed. Pfizer Inc. (NYSE:PFE)’s shares jumped by 1.8% earlier this week after the firm announced that its bladder cancer drug Padcev helped improve bladder cancer survival rates when combined with Merck’s […]",
      "url": "https://finnhub.io/api/news?id=e648541a1fdef3b7c8f532dcc7dabef45ee06cc247753bd47fc43993154e930d"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness",
    "summary": "We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc. (NYSE:MRK)’s shares have lost 16% year-to-date as investors continue to be disappointed by the dropping revenue of its GARDASIL HPV drug in China. They […]",
    "url": "https://finnhub.io/api/news?id=858c632a9b7797ea6f19fc63e9aa2cb46fc2e8e4e0cf66cb420301388d48c74a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755282638,
      "headline": "Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness",
      "id": 136376322,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc. (NYSE:MRK)’s shares have lost 16% year-to-date as investors continue to be disappointed by the dropping revenue of its GARDASIL HPV drug in China. They […]",
      "url": "https://finnhub.io/api/news?id=858c632a9b7797ea6f19fc63e9aa2cb46fc2e8e4e0cf66cb420301388d48c74a"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Merck, Palo Alto Networks, Freeport-McMoRan and Espey",
    "summary": "Analysts spotlight Merck, Palo Alto Networks, Freeport-McMoRan, and Espey as innovation, contract wins, and industry trends shape growth prospects.",
    "url": "https://finnhub.io/api/news?id=e197d1369f7ac384bfac43ab4a9f033fb4547e4cef7e562eb49b2a4a9d8b8fe6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755272640,
      "headline": "The Zacks Analyst Blog Highlights Merck, Palo Alto Networks, Freeport-McMoRan and Espey",
      "id": 136376323,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Analysts spotlight Merck, Palo Alto Networks, Freeport-McMoRan, and Espey as innovation, contract wins, and industry trends shape growth prospects.",
      "url": "https://finnhub.io/api/news?id=e197d1369f7ac384bfac43ab4a9f033fb4547e4cef7e562eb49b2a4a9d8b8fe6"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs",
    "summary": "AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.",
    "url": "https://finnhub.io/api/news?id=8c7ecaa4347c659d636f57fb74c8536477449124626665b52fa7ca9f7ad73eeb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755266400,
      "headline": "AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs",
      "id": 136370262,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.",
      "url": "https://finnhub.io/api/news?id=8c7ecaa4347c659d636f57fb74c8536477449124626665b52fa7ca9f7ad73eeb"
    }
  },
  {
    "ts": null,
    "headline": "UnitedHealth, Salesforce share gains contribute to Dow's 213-point climb",
    "summary": "UnitedHealth, Salesforce share gains contribute to Dow's 213-point climb",
    "url": "https://finnhub.io/api/news?id=789f6102b1ee49af7f4bba603f2f3318eec7def2fabac8cf271a24f8b118e015",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755251100,
      "headline": "UnitedHealth, Salesforce share gains contribute to Dow's 213-point climb",
      "id": 136385206,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "UnitedHealth, Salesforce share gains contribute to Dow's 213-point climb",
      "url": "https://finnhub.io/api/news?id=789f6102b1ee49af7f4bba603f2f3318eec7def2fabac8cf271a24f8b118e015"
    }
  },
  {
    "ts": null,
    "headline": "Branded Pharmaceuticals Stocks Q2 In Review: Merck (NYSE:MRK) Vs Peers",
    "summary": "Wrapping up Q2 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Merck (NYSE:MRK) and its peers.",
    "url": "https://finnhub.io/api/news?id=145ea4903178f0b2e0ac8e63c7471d7215c366bb911fe1663d42200cd020dab3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755228900,
      "headline": "Branded Pharmaceuticals Stocks Q2 In Review: Merck (NYSE:MRK) Vs Peers",
      "id": 136368084,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Wrapping up Q2 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Merck (NYSE:MRK) and its peers.",
      "url": "https://finnhub.io/api/news?id=145ea4903178f0b2e0ac8e63c7471d7215c366bb911fe1663d42200cd020dab3"
    }
  },
  {
    "ts": null,
    "headline": "Looking For Yields: Avista, Merck, And Skyworks Solutions Are Consistent Moneymakers",
    "summary": "Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Avista, Merck, and Skyworks Solutions have rewarded shareholders for years and recently announced dividend increases. These ...",
    "url": "https://finnhub.io/api/news?id=54888b70b96a62fbd835be93112a70eaaa603f27e40e736cd5a17ae295a4511a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755223272,
      "headline": "Looking For Yields: Avista, Merck, And Skyworks Solutions Are Consistent Moneymakers",
      "id": 136368085,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Avista, Merck, and Skyworks Solutions have rewarded shareholders for years and recently announced dividend increases. These ...",
      "url": "https://finnhub.io/api/news?id=54888b70b96a62fbd835be93112a70eaaa603f27e40e736cd5a17ae295a4511a"
    }
  }
]